1. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study
- Author
-
Peter M. A. van Ooijen, Uraujh Yousaf-Khan, Kevin ten Haaf, Harry J. de Koning, Carlijn M. van der Aalst, Matthijs Oudkerk, Marjolein A Heuvelmans, Geertruida H. de Bock, Harry J.M. Groen, Rozemarijn Vliegenthart, Joan Walter, Kristiaan Nackaerts, Public Health, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Cardiovascular Centre (CVC)
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Lung Neoplasms ,Volume Doubling Time ,Sensitivity and Specificity ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Belgium ,SDG 3 - Good Health and Well-being ,BENEFITS ,medicine ,MANAGEMENT ,Humans ,030212 general & internal medicine ,Lung cancer ,Trial registration ,SMALL PULMONARY NODULES ,Early Detection of Cancer ,Aged ,Netherlands ,business.industry ,Incidence ,Incidence (epidemiology) ,Area under the curve ,Nodule (medicine) ,Middle Aged ,medicine.disease ,Predictive value ,lung cancer ,PROBABILITY ,030228 respiratory system ,HARMS ,SOCIETY GUIDELINES ,Multiple Pulmonary Nodules ,Female ,TRIAL ,Radiology ,SOLID NODULES ,medicine.symptom ,Tomography, X-Ray Computed ,business ,Lung cancer screening - Abstract
BackgroundThe US guidelines recommend low-dose CT (LDCT) lung cancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lung cancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.MethodsIn the Dutch-Belgian Randomized Lung Cancer Screening (NELSON) trial, 7295 participants underwent the second and 6922 participants the third screening round. We included participants with solid nodules that were registered as new or 3).ResultsOverall, 680 participants with 1020 low-risk and intermediate-risk new solid nodules were included. A total of 562 (55%) new solid nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lung cancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lung cancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume positive provided 100% sensitivity, 84% specificity and 27% positive predictive value for lung cancer.ConclusionsMore than half of new low-risk and intermediate-risk solid nodules in LDCT lung cancer screening resolve. At follow-up, growth assessment potentially combined with a volume limit can be used for risk stratification.Trial registration numberISRCTN63545820; pre-results.
- Published
- 2019
- Full Text
- View/download PDF